Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
STOK Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
STOK Stock 12 Month Forecast
Average Price Target
$35.75
▲(15.06% Upside)
| Highest Price Target$50.00 | Average Price Target$35.75 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$50
Buy
60.93%
Upside
Reiterated
01/21/26
Needham
$35
Buy
12.65%
Upside
Reiterated
01/12/26
We thought the enrollment update was a big positive and shortened the timeline to a potential U.S. approval - which naturally and partially achieves the goal of the expedited development discussions. While STOK still plans to discuss an expedited pathway with FDA (Vineland-3 data being the main issue), it seems pretty clear that the company wouldn't jeopardize a broad, disease-modifying label (i.e., inclusion of the Vineland-3 data) for an earlier approval. Our base case still assumes STOK would file on the entirety of the 52-week Ph3 (as described in the updated timeline above), but a more expedited scenario would be an upside driver to the stock in our view. We spoke with mgmt for additional details and provide additional color below.
Chardan Capital
$35
Buy
12.65%
Upside
Reiterated
01/05/26
Jefferies
$30
Buy
-3.44%
Downside
Reiterated
11/24/25
TD Cowen
Buy
―
Reiterated
11/04/25
J.P. Morgan
$15→$25
Hold
-19.54%
Downside
Reiterated
11/03/25
Leerink Partners
$18→$30
Buy
-3.44%
Downside
Reiterated
10/07/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$50
Buy
60.93%
Upside
Reiterated
01/21/26
Needham
$35
Buy
12.65%
Upside
Reiterated
01/12/26
We thought the enrollment update was a big positive and shortened the timeline to a potential U.S. approval - which naturally and partially achieves the goal of the expedited development discussions. While STOK still plans to discuss an expedited pathway with FDA (Vineland-3 data being the main issue), it seems pretty clear that the company wouldn't jeopardize a broad, disease-modifying label (i.e., inclusion of the Vineland-3 data) for an earlier approval. Our base case still assumes STOK would file on the entirety of the 52-week Ph3 (as described in the updated timeline above), but a more expedited scenario would be an upside driver to the stock in our view. We spoke with mgmt for additional details and provide additional color below.
Chardan Capital
$35
Buy
12.65%
Upside
Reiterated
01/05/26
Jefferies
$30
Buy
-3.44%
Downside
Reiterated
11/24/25
TD Cowen
Buy
―
Reiterated
11/04/25
J.P. Morgan
$15→$25
Hold
-19.54%
Downside
Reiterated
11/03/25
Leerink Partners
$18→$30
Buy
-3.44%
Downside
Reiterated
10/07/25
Best Analysts Covering Stoke Therapeutics
3 Months
xxx
Success Rate
7/11 ratings generated profit
Average Return
+20.29%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +20.29% per trade.
1 Year
Success Rate
10/13 ratings generated profit
Average Return
+101.95%
reiterated a buy rating 19 days ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +101.95% per trade.
2 Years
xxx
Success Rate
14/15 ratings generated profit
Average Return
+109.81%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +109.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
STOK Analyst Recommendation Trends
Rating
Aug 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
6
6
5
4
6
Buy
14
23
31
30
34
Hold
2
1
17
16
20
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
30
53
50
60
Each month's total comprises the sum of three months' worth of ratings.
STOK Financial Forecast
STOK Stock Forecast FAQ
What is STOK’s average 12-month price target, according to analysts?
Based on analyst ratings, Stoke Therapeutics Inc’s 12-month average price target is 35.75.
What is STOK’s upside potential, based on the analysts’ average price target?
Stoke Therapeutics Inc has 15.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is STOK a Buy, Sell or Hold?
Stoke Therapeutics Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is Stoke Therapeutics Inc’s price target?
The average price target for Stoke Therapeutics Inc is 35.75. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $25.00. The average price target represents 15.06% Increase from the current price of $31.07.
The highest analyst price target is $50.00 ,the lowest forecast is $25.00. The average price target represents 15.06% Increase from the current price of $31.07.
What do analysts say about Stoke Therapeutics Inc?
Stoke Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of STOK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.